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Abstrac t
Migraine  as  a  highly  disabling  pain  condition  influences  the  daily
activities  of  those  affected,  including  children  and  adolescen t s .
The  pathom ec h a n is m  of  migraine  is  not  fully  unders tood,  and  the
differen t  types  of  prophylactic  antimigraine  drugs  that  are  applied  are  not
specific  for  migraine .  There  is  a  need  for  preventive  trea tm e n t  in  the
event  of  frequen t  migraine  attacks ,  an  impairm en t  of  the  quality  of  life,
severe  accompanying  or  aura  symptoms,  and  the  failure  of  acute  drug
trea tm e n t .  The  following  pharm acological  classes  are  recomm e n d e d :
antidepr e ss a n t s ,  antiepilept ics,  antihis tamines ,  beta- adrene r gic  recepto r
blockers  and  calcium  ion  channel  antagonis t s ,  besides  onabotulinum  toxin
A and  nutrace u t icals  (butte rbu r ) .  
The  most  urgen t  goal  as  concerns  pharma ce u t ical  innovation  is  the
developme n t  of  pathomec h a ni s m- based  antimigraine  drugs  and
personalized  therapy  tailored  to  the  children  and  adolescen t s .
Keyword s:  antidepr e ss a n t s ,  antiepileptics ,  antihistamines ,  beta-
adrene r gic  recep to r  blockers ,  butte rbu r ,  calcium  ion  channel  antagonis t s ,
efficacy,  migraine ,  onabotulinum  toxin  A,  pedia t r ic,  prophylactic,  safety,
therapy,  tolerability
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Introd u c t i o n
Migraine  is  a  highly  devasta t ing  neurovascula r  primary  headache
disorde r  that  can  affect  subjects  from  childhood  onwards  [1 , 2 ].  
The  Headache  Classification  Commit tee  of  the  Interna t ional  Headach e
Society  (IHS)  [3 ]  has  classified  migraine  into  subtypes:  migraine  without
aura,  migraine  with  aura,  chronic  migraine,  complica tions  of  migraine ,
probable  migraine  and  episodic  syndrom es  that  may  be  associa t ed  with
migraine .  The  earlier  name  of  this  last  subtype  was  childhood  periodic
syndromes  that  are  commonly  precursors  of  migraine  [ 3 ].  Episodic
syndromes  that  may  be  associat ed  with  migraine  are  furthe r  subdivided:
recur r e n t  gast roin t es t inal  disturba nce :  cyclic  vomiting  syndrome  and
abdominal  migraine ,  benign  paroxysmal  vertigo  and  benign  paroxysmal
torticollis  [3 ].  In  young  patient s ,  migraine  may  occur  with  or  without  aura
and  there  may  be  an  increase d  risk  of  the  developme n t  of  either  of  these
disorde rs  [3 ].  A  recen t  retrospec t ive  study  demons t r a t e d  that  the
prevalence  of  episodic  syndromes  that  may  be  associa ted  with  migraine
was  5.6%  [4 ].  The  most  frequen t  types  of  migraine  are  migraine  without
aura  and  migraine  with  aura.  The  typical  clinical  featu re s  are  a  dura t ion
of  4-72  hours ,  a  unilate r a l  localization,  a  pulsa ting  quality  and  modera t e
to  severe  intensi ty,  worsening  in  respons e  to  routine  physical  activity,
and  usually  combined  with  nausea ,  vomiting,  and/or  photophobia  and
phonophobia  as  concomitan t  symptoms  of  the  headach e  [3 ].  In  the  event
the  occur re nc e  of  migraine  aura,  visual,  sensory  or  other  cent ral  nervous
system  symptoms  develop  gradually  and  tempora r ily,  usually  preceding
the  headac he  phase  [3 ].  Chronic  migraine ,  one  of  the  devast a t ing
subtypes  of  migraine ,  has  a  considera ble  influence  on  the  quality  of  life,
even  in  young  patient s  [5 ,  6 ].  By  definition,  chronic  migraine  is  the
persis tence  of  headache  for  at  least  15  days  per  month  (migraine  quality
on  at  least  8  days)  and  for  at  least  3  consecu tive  months  [3 ].  
In  pedia t ric  migraine  patient s ,  the  dura tion  of  the  migraine  attack  may  be
shorte r ,  the  location  of  the  pain  is  often  bilate r al,  and  abdominal  pain,
nausea  and  vomiting  are  more  frequen t  [7 ].  The  diagnosis  of  migraine  in
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children  and  adolescen t s  is  therefore  rathe r  difficult,  and  the  IHS
diagnos t ic  criteria  are  broade r  than  in  adults  [7 , 8 ].  
The  impor tanc e  of  migraine  in  childhood  is  reflec ted  by  the  fact  that  a
majority  of  the  headache  cases  observed  in  the  pedia t ric  emerge ncy
depar t m e n t  involve  migraine  [9 ].  Epidemiological  data  have  revealed  that
40%  of  headach es  are  primary  headach es ,  75%  of  these  cases  being
migraine  [9 ].  Clinical  studies  have  demons t r a t e d  that  the  prevalence  of
migraine  increases  with  age,  [1 ,  10 ] 3%  or  less  in  those  up  to  7  years  old,
11%  among  11  - year  – olds,  and  23- 28%  in  adolescen t s  (13- 18  years  old)
[1 , 10 ]. In  a  large  cohor t ,  of  children  the  prevalence  of  migraine  proved  to
be  10.1%,  and  that  of  migraine  with  aura  1.6%  [11 ].  The  prevalence  of
migraine  depends  on  the  age  and  the  gende r .  The  sex  ratio  of  migraine
patient s  is  1:1  (boys:girls)  in  childhood,  the  ratio  subseque n t ly  increasing
with  the  progress ion  of  age  to  1:3  (males:fem ales)  [11 ].  The  mean  age  of
onset  of  migraine  is  7.2  years  in  boys  and  10.9  years  in  girls  [1 ].
The  pathom ec h a n is m  of  migraine  has  not  been  clearly  elucidat e d ,  but
activation  and  sensi tization  of  the  trigeminovascula r  system  and  distinct
neurope p tides  are  deeply  involved  [12- 15 ] (Figure  1).
In  conseque nc e  of  the  lack  of  knowledge  the  precise  pathogen e si s  of  the
initiation  and  the  recur r e nc e  of  migraine  attacks ,  specific  antimigra ine
prophylact ic  trea tm e n t  is  not  available  [16- 19 ].  In  everyday  pedia t ric
clinical  practice,  the  recomm e n d e d  drugs  for  the  prevention  of  migraine
headach e  attacks  are  antidep re s s a n t s  (amitriptyline  (AMI)  and
nort rip tyline  (NOR)),  antiepilep tics  (valproa te s ,  VALPs;  topiram a t e ,  TOP;
levetirace t a m,  LEV;  zonisamide,  ZON;   and  gabape n t in,  GBP),
antihis tamine s  (cyprohep t a dine ,  CYP),  beta- adrene rgic  recep to r  blockers
(propranolol,  PROP)  and  calcium  ion  channel  antagonis t s  (flunarizine,
FLUN)  [7 ,  20 ].  Onabotulinum  toxin  A (OBOT- A) has  recently  been  applied
for  the  alleviation  of  chronic  migraine  in  children  and  adolescen t s  [ 21-
23 ],  and  butte rb u r  may  be  mentioned  as  a  nutrace u t ical .
This  review  discusses  the  drugs  curren t ly  used  in  the  preven tive  therapy
of migraine  in  children  and  adolescen t s .
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Prophylac t i c  drug  treat m e n t  in  pediatri c  migra in e
The  indications  of  prophylactic  migraine  therapy  include  a  high  frequency
of  migraine  attacks,  an  impairme n t  of  the  quality  of  life  and  of  the
regula ri ty  of  school  attenda nc e ,  the  ineffective,  not  tolera t ed ,
contraindica t ed  or  overused  acute  manage m e n t  of  headache  attacks ,  or
the  presence  of  complex  and  severe  accompanying  symptoms  or  long
uncomfor ta bl e  aura  symptoms  [1 ,  7 ,  16 ,  17 ].  The  fundam e n t a l  aims  of
antimigraine  trea tm e n t  are  a  decreas e  of  the  attack  frequency  by  at  least
50%  within  3  months  and  a  diminution  of  the  dura t ion  and  intensi ty  of  the
head  pain  [1 ,  17 ].  Although  around  one- third  of  adolescen t s  need
prophylact ic  antimigraine  therapy,  only  10- 19%  are  offered  it  [ 24 ].  For
this  special  popula tion,  the  paren t s  or  other  family  member s  should  be
educa ted  as  to  the  effects  and  possible  adverse  events  (AEs)  of  the  drugs
and  the  drug  titra tion  and  dosing  schedule  [25 ].  Avoidance  of  the  side-
effects  of  the  drugs  demands  slow  titra tion  (4-12  weeks)  and  the
trea tm e n t  period  is  sugges t e d  to  be  at  least  6-8  weeks  [ 25 ].  In  genera l,  it
is  very  import an t  that  the  pharm acological  trea tm e n t  of  young  migraine
patient s  should  be  accompa nied  by  psychological  suppor t  for.
Antidepr e s s a n t s
Amitriptyline
AMI,  a  tricyclic  antidepr e s s a n t ,  has  a  multiple  mode  of  action,  which
includes  the  blockade  of  norepineph r ine  and  serotonin  reuptake ,  togethe r
with  anticholinergic,  histamine rgic  and  gamma- aminobutyric  acid
(GABA)-ergic  effects  [26 ,  27 ].  AMI  influences  the  antinocicep tive  function
via  activation  of  the  adenosine  A1  recepto r  and  enhance s  neuronal
sensi tivity  to  subst ance  P  (SP)  [19 ].
In  the  prophylact ic  trea tm e n t  of  pedia t ric  migraine ,  AMI  is  one  of  the
most  widely  used  pharm acons  despite  the  performa nc e  of  only  a  low
number  of  randomized  clinical  trials.  A recent  large  academic  hospital
study  revealed  that  AMI  was  the  most  common  preventive  medicat ion
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prescribed  to  pedia t ric  patient s  with  migraine  either  with  or  without  aura
[28 ].  In  a  study  where  low- dose  AMI  or  PROP  was  added  to
nonpha r m a cological  therape u t ic  measur e s  (e.g.  relating  to  sleep  hygiene,
dietetic  and  lifestyle  recomm e n d a t ions ,  or  sun  exposure) ,  it  was
concluded  that  the  both  two  drugs  were  equally  effective  in  reducing  the
frequency  of  pedia t ric  migraine  [29 ].  A double- blind  placebo- controlled
multicen te r  compara t ive  effectiveness  study  of  AMI  and  TOP  is  ongoing
(Childhood  and  Adolescen t  Migraine  Preven tion  Study,  CHAMP),  with  the
aim  of  a  50%  reduc tion  in  migraine  frequency  in  children  and  adolescen t s
as  primary  outcome  [30 ].  The  first  resul ts  are  planned  to  be  published  in
2016.  A  prospec tive  trial  has  led  to  the  finding  that  suppleme n t a ry
vitamin  D therapy  in  addition  to  AMI  significantly  reduces  the  number  of
migraine  attacks  in  pedia t r ic  migraine  patient s  [31 ].  A  randomized
clinical  trial  focusing  on  the  effects  of  cognitive  behavioral  therapy  (CBT)
plus  AMI  versus  headach e  educa tion  plus  AMI  in  chronic  migraine
pediat r ic  patient s  proved  that  the  reduc tion  in  the  number  of  headach e
days  was  superior  in  the  CBT  plus  AMI  group  [32 ].
The  recomm e n d e d  dose  of  AMI  is  10- 150  mg  qhs  (“every  night  at
bedtime”)  (at  most  1  mg/kg/day)  [7 ].  The  reason  for  the  bedtime  dosing  is
the  somnolence  that  occurs  as  one  of  the  most  common  side- effects  of  the
drug  [25 ,  33 ].  Other  frequen t  AEs  are  dizziness,  constipa t ion,  an
increas ed  appeti t e  and  a  weight  gain  [7 ].  AMI  is  prefe r r ed  in  view  of  its
relatively  favorable  side  effect  profile  and  dosing  regime  [ 33 ].  The
recomm e n d a t ion  levels  of  migraine  prophylact ic  drugs  are  based  on  the
repor t s  of  the  Scientific  Task  Force  of  the  Europea n  Federa t ion  of
Neurological  Societies  and  the  Quality  Standa r d  Subcom mit t e e  of  the
American  Academy  of  Neurology  and  the  American  Headach e  Society
[34 ,  35 ].  The  recomm e n d a t ion  level  of  AMI:  Class  IV,  Level  U  [ 25 ] (Table
1.).  
Nortriptyline
In  actual  medical  practice  instead  of  AMI  may  be  replaced  by  NOR,  which
has  a  lower  sedative  effect,  but  mention  must  be  made  of  its  significant
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poten tial  cardiac  side  effect  (arrhythmia)  [7 ,  25 ].  The  recomm e n d e d  dose
of  NOR  is  10- 75  mg  qhs  [7 ].
Antiep i l e p t i c s
Valproates
The  VALPs  consis t  of  valproic  acid,  sodium  valproat e  and  some
combina tion  of  these  drugs.  They  strongly  block  the  periphe ra l  and
centra l  trigeminovascula r  responses  and  nociceptive  transmission,  exert
a  great  influence  on  the  cortical  neuronal  hyperexcitabili ty  and  suppress
cortical  spreading  depres sion  via  the  GABA-A recep to r  [36 , 37 ].
A  prospec tive  randomized  clinical  trial  in  which  PROP  and  sodium
valproat e  were  compared  as  concerns  their  efficacy  in  preven tive
migraine  trea tm e n t  in  children  and  adolescen t s  found  no  significant
difference  between  these  two  drugs  in  mean  headache  dura tion  per  week,
in  headache  severi ty,  or  in  the  complete  cessa t ion  of  headache  attacks.
The  mean  headac he  frequency  per  month  was  lower  in  the  PROP  group
than  in  the  sodium  valproat e  group.  As regards  the  side- effects ,  there  was
no  significan t  difference  between  the  two  drugs  [ 38 ].  Doses  of  15- 20
mg/kg/day  appea r  to  be  effective.  The  common  AEs  of  VALPs  are
somnolence ,  a  skin  rash,  a  weight  gain,  tremor,  drowsiness ,  hair  loss,  and
hematological  or  liver  abnorm ali ties  [39 ,  40 ].  Due  to  their  tera toge nici ty,
VALPs  cannot  be  recom me n d e d  for  females  of  reproduc tive  age  [19 ].  A
recen t  meta- analysis  focusing  on  the  pharm acological  preventive
trea tm e n t  of  pedia t r ic  migraine  indicated  that  VALPs  were  found
ineffective  in  reducing  the  number  of  headache s  per  month  [ 41 ].  The
recomm e n d a t ion  level  of  VALPs:  Class  IV, Level  U  [25 ].
Topiramate
As  concerns  migraine,  TOP  influences  the  pain  transmission  in  the
trigeminoce rvical  complex  and  the  third- order  neurons  in  the
ventropos t e ro m e dia l  thalamus  [37 ].
A prospec tive  clinical  study  concluded  that  a  low  prophylac tic  dose  (<2
mg/kg/day)  of  TOP  is  effective  in  reducing  the  mean  frequency,  dura tion
and  intensi ty  of  pedia t r ic  migraine  [42 ].
A randomized  compara t ive  clinical  trial  demons t r a t e d  that  TOP  and  PROP
treatm e n t  displayed  the  same  efficiency  in  reducing  the  headac he
frequency  and  the  severi ty  and  dura tion  of  migraine  attacks  in  childhood
[43 ].
In  a  furthe r  clinical  study,  TOP  proved  effective  (the  monthly  frequency,
severi ty  and  dura tion  of  migraine  headach e  were  all  decreas e d)  and  safe
for  the  prophylaxis  of  migraine  in  children  [44 ].  A  ret rospec t ive
compara t ive  trial  revealed  that  the  effects  of  FLUN  and  TOP  did  not  differ
significantly  as  concerns  the  total  numbe r  of  headach e  days  per  month  in
preadolesce n t  and  adolescen t  migraine  patient  groups  with  or  without
aura  [45 ].
A  recent  review  concluded  that  TOP  is  effective  in  decreas ing  the
frequency  of  headache s  in  pedia t ric  migraine  patient s  [46 ].  A  > 50%
reduc tion  in  migraine  rate  was  attained  in  83- 95%  of  the  patient s .  The
recomm e n d e d  dose  of  TOP  is  1-10  mg/kg/day,  with  a  genera l  dose  of  50
mg  bid  (twice  per  day)  [7 ].  TOP  is  well  tolera te d;  its  common  AEs  are
numbness ,  a  weight  loss,  a  cognitive  impairme n t  (affecting  the  verbal
fluency,  concen t r a t ion  and  working  memory),  fatigue,  nausea  and
somnolence  [47 ].  The  recomm e n d a t ion  level  of  TOP:  Class  IV,  Level  U
[25 ].
Levetirace ta m
LEV  is  a  pyrolidone  derivative  with  an  antiepilep tic  effect.  It  has  a  novel
and  appare n t ly  unique  mechanis m  of  action,  which  may  be  associa ted
with  its  binding  to  synaptic  vesicle  protein  SV2A,  therefore  influencing
the  neurot r a ns mi t t e r  release  [48 ].  
An  early  small  ret rospec t ive  study,  on  the  efficacy  of  LEV  in  pedia t ric
migraine  pointed  to  its  beneficial  effect  (in  10  of  19  children  and
adolescen t s ,  LEV  eliminated  the  migraine  headache)  [ 49 ].  An  open  label
study  led  to  the  conclusion  that  LEV reduced  the  frequency  of  migraine:  a
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more  than  50%  decreas e  in  the  frequency  of  monthly  headach es  and  was
achieved  (in  18  of  20  patien ts) ,  and  the  Pedia t r ic  Migraine  Disability
Assessme n t  Test  (PedMIDAS)  revealed  a  significan t  decreas e  in  disability
as  compare d  with  the  baseline  in  pedia t ric  migraineu r s  [50 ].  The
recomm e n d e d  daily  dose  of  LEV  is  500- 1500  mg  bid  [ 7 ,  20 ].  Its  safety
profile  appea r s  accep ta ble,  but  its  common  AEs  include  somnolence ,
fatigue,  irritabili ty  and  dizziness  [7 ,  20 ,  25 ].  The  recomm e n d a t ion  level  of
LEV:  Class  IV, Level  U  [25 ].
Zonisamide
ZON  is  a  synthe t ic  1,2- benzisoxazole- 3-methane s ulfona mide ,  which  acts
by  inhibiting  the  voltage- sensi tive  sodium  and  reducing  the  voltage-
sensi tive  T-type  calcium  channels  [51 ].
A very  small  retrospec t ive  study  sugges t e d  that  ZON  had  the  capability  to
reduce  the  headach e  frequency  in  refrac to ry  pediat r ic  headache  patien ts
(8  of  12  patient s  responded  favorably)  [52 ].  The  recomm e n d e d  dose  of
ZON  is  100- 600  mg  per  day  [7 ,  20 ].  Its  common  AEs  are  dizziness,
nausea ,  irritability  and  somnolence  [7 ,  20 ].  The  recomm e n d a t ion  level  of
ZON:  Class  IV, Level  U  [25 ].  
Gabapen tin
GBP  is  structu r a lly  related  to  GABA,  but  without  any  direc t  effects  on
GABA or  any  of  its  recepto r s  [53 ].  There  have  been  only  very  rare  clinical
studies  of  GBP  in  pedia t r ic  migraine .  Belman  et  al.  repor t ed  data  on  18
migraine  children  trea t ed  with  GBP,  80%  of  whom  attained  a  more  than
50%  reduction  in  migraine  frequency  [20 ,  54 ].  The  recomm e n d e d  dose  of
GBP  is  300- 1200  mg  three  times  daily  (tid)  [20 ].  The  common  AEs  of  GBP
are  seda tion,  ataxia,  fatigue  and  periphe ra l  edema  [20 ].  The
recomm e n d a t ion  level  of  GBP:  Class  IV, Level  U  [25 ].  
Antihi s ta m i n e s
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Cyprohep tadine
CYP  exert s  antihis tamine r gic ,  antise ro tonine r gic  and  anticholinergic
actions,  and  has  the  ability  to  block  (competi t ively  and  reversibly
antagonize)  the  histamine  and  serotonin  recepto rs  [55 ].  The  5-
hydroxytrypta mine  1B  and  1D  recep to r s  take  part  in  the  activation  of  the
trigeminovascula r  system  via  cerebrovascula r  vasocons t r ic tion  and
inhibition  of  the  release  of  vasoac tive  neurope tides ,  e.g.  calcitonin  gene-
related  peptide  (CGRP),  SP  and  pituita ry  adenyla te  cyclase- activating
polypeptide  (PACAP)  [2 , 18 , 56 , 57 ].
In  a  double- blind  controlled  study  in  which  patien ts  aged  16  to  53  years
(mean  28.6)  received  CYP  as  prophylac tic  trea tm e n t  of  migraine ,  the
mean  headache  frequency  decreas e d  from  8.4  to  3.7  per  month,  with  an
overall  positive  response  rate  of  83%  [58 ].  A recen t  retrospec t ive  clinical
study  led  to  the  finding  that  CYP was  effective  in  abdominal  migraine  and
in  cyclic  vomiting  syndrome  (among  the  functional  gast roin te s t inal
disorde rs ),  the  responde r  rate  proving  to  be  high:  in  abdominal  migraine
13  of  18  pediat r ic  patient s  (72%)  and  in  cyclic  vomiting  syndrom e  6  of  8
patient s  (75%)  exhibited  a  clinical  improvem e n t  [ 59 ].  CYP  is  available  as
tablet s  and  liquid  suspensions ,  with  recomm e n d e d  doses  of  0.25- 1.5
mg/kg/day  [20 ].  The  most  common  side- effects  of  CYP  are  sleepiness ,  a
weight  gain  and  an  increas ed  appeti t e  [ 7 ,  33 ,  59 ].  An  investiga t ion  by  a
large  academic  children’s  hospital  of  the  prescrip tion  pat te rn s  in  patien t s
aged  2-17  years  demons t r a t e d ,  that  the  one  of  the  most  common  by
prescribed  medicat ions  for  pedia t ric  migraine  prophylaxis  was  CYP  [ 28 ].
The  recomm e n d a t ion  level  of  CYP:  Class  IV, Level  U  [25 ].
Beta- adren er g i c  recep t or  block er s
Propranolol
PROP,  a  nonselect ive  beta- adrene r gic  recepto r  blocker  that  inhibits  the
third- order  trigeminovascula r  nociceptive  neurons  in  the
ventropos t e ro m e dia l  nucleus  of  the  thalamus  [19 ,  60 ],  has  a  long  history
10
of use  in  migraine  prophylaxis  in  children  [61 ].  The  resul ts  emerging  from
clinical  trials  have  been  conflicting  [1 , 25 ].
In  recent  studies,  PROP  has  been  widely  used  as  a  compara t ive
pharm acon.
In  a  prospec t ive  randomized  trial  which  compare d  the  prophylac tic  anti-
migraine  effects  of  PROP  an  VALP  in  children  (aged  5-15  years)  with
migraine  without  aura,  VALP  was  found  to  be  superior  to  PROP  only  in
reducing  the  mean  headache  frequency  per  month  [38 ].  Low- dose  PROP
and  low- dose  AMI  proved  equally  effective  in  reducing  the  frequency  of
severe  migraine  attacks  in  pedia t r ic  migraineu r s  (mean  age  12.54  years),
but  it  was  notewor t hy  that  PROP  had  fewer  side- effects  [29 ].  A
randomized  clinical  compara t ive  trial  relating  to  childhood  migraine
prophylaxis  revealed  that  TOP  and  PROP  displayed  the  same  efficacy  in
reducing  the  frequency,  severi ty  and  dura tion  of  migraine  attacks  [ 43 ].  In
contras t ,  anothe r  parallel  single- blinded  randomized  clinical  trial
involving  5-15- year- old  migraineu r s  revealed  that  TOP  was  more  effective
than  PROP  in  reducing  the  monthly  frequency,  severi ty  and  dura t ion  of
headach e  and  in  the  PedMIDAS  score.  Both  drugs  exer ted  transien t  and
mild  side- effects  [62 ].  A recent  compar a t ive  randomized  controlled  trial
that  focused  on  the  effects  of  PROP  as  compare d  with  pregaba lin  in
pediat r ic  migraine  led  to  the  result  that  pregab alin  reduced  the  headache
frequency  considera bly  more  effectively  than  did  PROP  [63 ].
The  recomm e n d e d  dose  of  PROP  is  2-4  mg/kg/day.  The  most  common
side- effects  are  hypotension,  depress ion  and  dizziness  [7 ,  20 ].  The
unfavorable  AEs  of  PROP  have  limited  its  wide- ranging  use  in  young
migraineu r s  [25 ].  The  recomm e n d a t ion  level  of  PROP:  Class  II,  Level  U
[25 ].  
Calciu m  ion  chan n e l  anta g o n i s t s
Flunarizine
FLUN  is  a  nonselec t ive  calcium  ion  entry  blocker  that  mainly  acts  via  T-
type  ion  channels  [64 ].  Its  exact  mechanism  of  action  in  migraine  is  still
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unknown,  but  it  may  involve  smooth  muscle  inhibition  in  the  vascula tu r e
and  effects  on  neuronal  activation  via  5-hydroxytryp ta mine  antagonism
[65 ].
A classical  double- blind,  placebo- controlled,  crossover  study  revealed  that
FLUN  was  effective  in  the  prophylaxis  of  childhood  migraine  [66 ].
A  single- cente r  retrospec t ive  observa t ional  study  which  evaluat ed  the
effects  of  FLUN  in  various  subtypes  of  childhood  migraine,  i.e.  migraine
without  aura,  migraine  with  aura,  sporadic  and  familial  hemiplegic
migraine ,  found  that  FLUN  was  more  effective  in  the  hemiplegic  migraine
group  [67 ].
With  the  focus  on  disability  and  the  quality  of  life  of  pediat r ic
migraineu r s ,  FLUN  trea tm e n t  significantly  decreas e d  the  PedMIDAS
score,  but  in  the  same  study,  FLUN  was  inferior  to  TOP  and  PROP  in  the
PedMIDAS  system  [68 ].
The  recomm e n d e d  dose  of  FLUN  is  5-10  mg  qhs  [7 , 20 ].  The  common  AEs
of  FLUN  are  sedation,  a  weight  gain,  fatigue  and  gast roin te s t inal
discomfor t  [7 , 20 , 25 ].  
The  recomm e n d a t ion  level  of  FLUN:  Class  I,  Level  B [25 ].
Onabot u l i n u m  toxin  A
One  of  the  lates t  therape u t ic  regimes  for  adult  migraine  patient s  is
OBOT- A injection  trea tm e n t ,  which  was  approved  by  the  US  Food  and
Drug  Adminis t ra t ion  in  2010  [69 , 70 ].  
Botulinum  neurotoxin- A is  a  purified  neurotoxin  complex  produced  by  the
anaerobic  bacte rium  Clostridium  botulinu m  [71 ,  72 ].  The  main
mechanism  of  action  of  botulinum  toxin  involves  the  targe t ing  of  the
neuromusc ula r  junctions  by  means  of  a  specific  cleavage  of  the  soluble  N -
ethylmaleimide- sensitive  factor  (NSF)- attachm e n t  protein  recep to r
complex  (SNARE)- like  synaptosom al- associa ted  protein  of  25  kDa  (SNAP-
25)  [71 ,  72 ].  The  final  outcome  of  this  multistage  process  is  the  breaking
of  pain  neurot r an s miss ion,  including  the  inhibition  of  the  release  of
migraine- related  neurope p tides  (e.g.  CGRP  and  SP)  and  glutama t e  [ 71-
74 ].
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The  prevalence  of  chronic  migraine  among  pediat r ic  migraineu r s  is
around  3%  [23 ].  A retrospec t ive  case  series  study  of  the  use  of  OBOT- A
for  the  trea tm e n t  of  refrac to ry  pediat r ic  chronic  daily  headache ,
including  chronic  migraine ,  revealed  that  4  of  10  patien ts  repor t ed  a
decreas e  in  headach e  intensi ty  and  2  of  them  decreas e  in  headach e
frequency,  and  these  4  responde r  patients  achieved  a  favorable
improveme n t  of  the  quality  of  life  [21 ].  A ret rospec t ive  review  of  the  data
on  45  pedia t ric  chronic  daily  headach e  patient s  who  participa t ed  in  252
OBOT- A injections  (average  dose  188.5  +  32  units)  concluded  that  the
monthly  headac he  frequency  was  decreas ed  and  the  PedMIDAS  score
showed  an  improveme n t  [23 ].  A recen t  small  case  series  study  of  chronic
migraineu r s  (aged  13- 17  years)  showed  a  good  responde r  rate  (7  of  10
patient s) .  The  number  of  headache  days  per  month  decreas ed  from  19.2
to  10.1  [22 ]. The  recomm e n d e d  dose  of  OBOT- A is  100  units.  The  common
AEs  of  OBOT- A are  redness  or  tempora ry  pain  at  the  injection  site,  ptosis
and  blurred  vision  [25 ].  The  recomm e n d a t ion  level  of  OBOT- A: Class  IV,
Level  U  [25 ].
Nutrac e u t i c a l s  (Herbal  produ c t s )
Petasi tes  hybridus  (butterbur)
Extrac t s  of  the  roots  of  Petasi tes  hybridus  exert  an  anti- inflamma to ry
effect  via  the  inhibition  of  leukot riene  produc tion,  and  influence
intracellula r  calcium  accumula t ion  through  the  L-type  voltage- gated
calcium  ion  channels  [75 ].
A multicen te r  prospec tive  open- label  study  with  a  butte rbu r  root  extrac t
for  migraine  preven tion  (50- 150  mg  for  4  months),  which  involved  108
children  and  adolescen t s  (aged  6-17  years)  resul ted  in  77%  of  all  patient s
repor t ing  a  63%  decreas e  in  frequency  of  migraine  attacks  [ 76 ].  A
prospec tive,  randomized,  par tly  double- blind,  placebo- controlled,  parallel-
group  trial  was  set  up  to  examine  the  prophylac tic  antimigraine  effects  of
butte rbu r  root  extrac t  and  music  therapy  in  primary  school  children  [ 77 ].
The  evaluation  of  this  study  revealed  that  both  the  butte rbu r  extrac t  and
music  therapy  were  superior  to  placebo  in  reducing  the  frequency  of
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headach e  attacks  in  the  follow- up  period  [77 ].  The  recomm e n d e d  dosage
of  butte rb u r  is  50- 150  mg  per  day.  The  main  AE  of  butte rbu r  extrac t  is
burping.  The  recomm e n d a t ion  level  of  Petasites : Class  II,  Level  U  [25 ].  
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Conclu s i o n
The  pathom ec h a n is m  of  migraine  is  not  fully  unders tood,  and
personalized  therapy  tailored  to  the  patient  is  therefore  not  available  for
pediat r ic  migraine.  A  further  difficulty  is  the  fact  that  the  lates t
therape u t ic  guidelines  were  published  more  than  ten  years  ago.  This
review  has  surveyed  the  lates t  litera tu r e  data  relating  to  the  prophylact ic
drugs  used  in  the  daily  clinical  practice  in  children  and  adolescen t s  with
migraine .  For  the  near  future ,  basic  experime n t a l  and  human  headache
resea rc h  is  needed,  such  as  innovative  pharm ac e u t ical  investme n t s  with
fully  humanized  monoclonal  antibodies  agains t  CGRP  and  CGRP
recepto r s .  Randomized  clinical  trials  are  still  necess a ry  as  rega rds
curren tly  used  prophylactic  antimigra ine  drugs  and  new  compounds
designed  for  the  trea tm e n t  of  young  migraineu r s .  Overall,  new
therape u t ic  guidelines  are  clearly  required  in  this  field.
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Table
Table  1  Prophylac t i c  drugs  reco m m e n d e d  in  pediatri c  migrai n e
Drugs Reco m m e n d e
d  daily  dosa g e
Com m o n  advers e  
event s
Reco m m e n d
ation  level
Antidepr e s s a n t s
Amitriptyline 10- 150  mg  qhs dizziness,  
constipat ion,  




Nortrip tyline 10- 75  mg  qhs cardiac  
(arrhythmia)
no  data
Antiep i l e p t i c s
Valproa t e s 15- 20  
mg/kg/day
somnolence ,  skin  
rash,  weight  gain,  
tremor,  drowsiness ,
hair  loss,  
hematological  or  
liver  abnorm ali t ies
Class  IV
Level  U
Topirama te 1-10  mg/kg/day numbne ss ,  weight  
loss,  cognitive  
impairme n t ,  




Levetirace t a m 500- 1500  mg  
bid
somnolence ,  




Zonisamide 100- 600  
mg/day





Gabapen t in 300- 1200  mg  
tid
seda tion,  ataxia,  




Antihi s ta m i n e s
Cyprohep t a dine 0.25- 1.5  
mg/kg/day
sleepiness ,  weight  
gain,  increas ed  
appe ti t e
Class  IV
Level  U
Beta- adren er g i c  recep t or  block er s
Propranolol 2-4  mg/kg/day hypotension,  




Calciu m  ion  chan n e l  anta g o n i s t s
Flunarizine 5-10  mg  qhs seda tion,  weight  
gain,  fatigue,  




Onabot u l i n u m  
toxin  A
100  units redness  or  




the  injection  site,  
ptosis,  blurred  
vision  
Nutrac e u t i c a l s  (herbal  produ c t s )
Petasi t es  
hybridus
(butte rb u r)
50- 150  mg/day burping Class  II
Level  U
Abbrevia tions:  qhs:  every  night  at  bedtime;  bid:  twice  daily;  tid:  three  
times  daily
Modified  from  Ref.  [7 , 20 , 25 ].
Figur e  lege n d s
Figur e  1  Sch e m e  of  the  activat io n  of  the  trige m i n o v a s c u l ar  syst e m
The  puta t ive  mechanism  of  activation  of  the  sensi tization  of  the
trigeminovascula r  system  is  the  following.  The  process  of  cortical
spreading  depre ss ion  (CSD),  a  slowly  propaga t ing  wave  of  neuronal  and
glial  depolariza t ion,  activates  trigeminal  nocicepto r s .  Activation  of
meningeal  afferen ts  leads  to  the  release  of  CGRP,  SP,  and  PACAP  via  the
periphe r a l  branch  of  the  trigeminal  pseudounipola r  neurons.  The
release d  substanc es  may  promote  neurogenic  inflamma tion  in  the
cereb ra l  dura  mate r  and  lead  to  activation  and  sensitiza tion  of  periphe ra l
meningeal  nerve  terminals,  the  nocicepto r s .  The  conseque n c e s  of
periphe r a l  sensitiza tion  include  the  cent ral  sensitiza tion  of  the  second-
order  neurons  in  the  trigeminoce rvical  complex  (TCC)  as  well  as  that  of
the  third- order  neurons  in  the  thalamus .  
Modified  from  Ref.  [2 , 78 ].
Abbrevia tions:  CGRP:  calcitonin  gene- related  peptide;  CSD:  cortical
spreading  depre ss ion;  PACAP:  pituita ry  adenyla te  cyclase- activating
polypeptide ;  SP:  substanc e  P;  TCC:  trigeminoce rvical  complex;  TRIG:
trigeminal  ganglion.
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